Thibaut Mongon - 23 Aug 2023 Form 4 Insider Report for Kenvue Inc. (KVUE)

Role
Chief Executive Officer, Director
Signature
/s/ Alla Berenshteyn, as attorney-in-fact
Issuer symbol
KVUE
Transactions as of
23 Aug 2023
Net transactions value
$0
Form type
4
Filing time
25 Aug 2023, 18:12:21 UTC
Previous filing
03 May 2023
Next filing
04 Oct 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KVUE Restricted Stock Units Award $0 +25,314 $0.000000 25,314 23 Aug 2023 Common Stock 25,314 Direct F1, F2
transaction KVUE Restricted Stock Units Award $0 +23,195 $0.000000 23,195 23 Aug 2023 Common Stock 23,195 Direct F1, F3
transaction KVUE Restricted Stock Units Award $0 +23,432 $0.000000 23,432 23 Aug 2023 Common Stock 23,432 Direct F1, F4
transaction KVUE Restricted Stock Units Award $0 +156,417 $0.000000 156,417 23 Aug 2023 Common Stock 156,417 Direct F5, F6
transaction KVUE Restricted Stock Units Award $0 +139,170 $0.000000 139,170 23 Aug 2023 Common Stock 139,170 Direct F3, F5
transaction KVUE Restricted Stock Units Award $0 +179,515 $0.000000 179,515 23 Aug 2023 Common Stock 179,515 Direct F4, F5
transaction KVUE Stock Options Award $0 +418,970 $0.000000 418,970 23 Aug 2023 Common Stock 418,970 $21.97 Direct F2, F7
transaction KVUE Stock Options Award $0 +458,189 $0.000000 458,189 23 Aug 2023 Common Stock 458,189 $22.40 Direct F3, F7
transaction KVUE Stock Options Award $0 +514,646 $0.000000 514,646 23 Aug 2023 Common Stock 514,646 $22.23 Direct F4, F7
transaction KVUE Stock Options Award $0 +432,986 $0.000000 432,986 23 Aug 2023 Common Stock 432,986 $20.44 Direct F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted share units ("RSUs") were originally granted by Johnson & Johnson and, in connection with the Issuer's separation from Johnson & Johnson on August 23, 20223 (the "Separation") and pursuant to the terms of the Employee Matters Agreement, dated as of May 3, 2023 between Johnson & Johnson and the Issuer (the "Employee Matters Agreement"), were converted into RSUs with respect to Issuer common stock with adjustments made to the number of shares subject to the award in order to preserve the award's value.
F2 This award vests in three equal installments on 02/13/2024, 02/13/2025, and 02/13/2026, subject to the reporting person's continued service through the vesting date.
F3 This award will vest in full on 02/14/2025, subject to the reporting person's continued service through the vesting date.
F4 This award will vest in full on 02/08/2024, subject to the reporting person's continued service through the vesting date.
F5 These RSUs were originally granted by Johnson & Johnson as performance share units and, in connection with the Separation and pursuant to the terms of the Employee Matters Agreement, were converted into time-based RSUs with respect to Issuer common stock with adjustments made to the number of shares subject to the award in order to preserve the award's value and with performance criteria deemed satisfied at the target level, unless two years have been completed in the performance period, in which case performance was deemed satisfied at the level of performance for such years.
F6 This award will vest in full on 02/13/2026, subject to the reporting person's continued service through the vesting date.
F7 These stock options were originally granted by Johnson & Johnson and, in connection with the Separation and pursuant to the terms of the Employee Matters Agreement, were converted into options with respect to Issuer common stock with adjustments made to the number of shares subject to the award and its exercise price in order to preserve the award's value.
F8 This award is fully vested